Recent News

Long-Term Outcomes With Standard-of-Care Strategy in Multiple Myeloma

Melphalan Flufenamide Receives Accelerated Approval for Resistant Multiple Myeloma

Taking on Myeloma and Prostate Cancer: A Man Named Steele

TCT 2021: Is Idecabtagene Vicleucel Safe for Elderly Patients With Resistant Myeloma?

Does a Patient’s Race Affect Access to IV Bisphosphonates in Multiple Myeloma?

Ixazomib Plus Standard Therapy for Myeloma: Outcomes in Routine Clinical Practice

Selinexor Triplet Under Study in Resistant Multiple Myeloma

Continued Trials for Iberdomide in Combination Therapy for Resistant Myeloma

Seeking the Right Dose of Immunoconjugate Combination in Resistant Myeloma

Corneal Changes With Antibody-Drug Conjugate in Myeloma: Mechanism Remains Unknown

Ixazomib Plus Standard Therapy in Transplant-Ineligible Patients With Myeloma

Cyclophosphamide Plus Weekly Carfilzomib and Dexamethasone in Resistant Myeloma

Carfilzomib-Based Therapy for High-Risk Smoldering Multiple Myeloma

Is Hypercalcemia Linked to Poor Survival in Newly Diagnosed Multiple Myeloma?

Investigational Immunotherapy Focus of Phase I Trial in Resistant Myeloma

ASH 2020: Intravenous and Subcutaneous Teclistamab for Resistant Multiple Myeloma

Selinexor Approved by FDA for Refractory or Relapsed Multiple Myeloma

ASH 2020: Ciltacabtagene Autoleucel Under Study in Resistant Myeloma

Daratumumab Plus Pomalidomide and Low-Dose Dexamethasone in Myeloma: Immune-Mediated Cytotoxicity

ASH 2020: Subcutaneous Daratumumab Plus Pomalidomide and Dexamethasone in Resistant Myeloma

Are Carfilzomib-Based Regimens Safe and Effective for Frail Patients With Myeloma?

ASH 2020: Novel Immunotherapy Plus Chemotherapy in Resistant Multiple Myeloma

ASH 2020: BCMA-Targeted Antibody-Drug Conjugate in Resistant Multiple Myeloma

Myeloma and COVID-19: Dana-Farber and Quest Diagnostics Collaborate on IMPACT Study

Trends in Myeloma by Age: Treatment and Outcome Disparities Explored

ARROW Trial: Once- or Twice-Weekly Carfilzomib Plus Dexamethasone in Myeloma

Ixazomib Plus Lenalidomide/Dexamethasone for Transplant-Ineligible Patients With Myeloma

ASTRO 2020: Low-Dose Radiotherapy for Painful Osseous Lesions in Patients With Myeloma

ASTRO 2020: U.S. Trends in Use of Palliative Radiotherapy for Myeloma

Novel Peptide-Drug Conjugate Plus Dexamethasone Under Study in Resistant Myeloma

Pegfilgrastim Versus Filgrastim for Heavily Pretreated Patients With Multiple Myeloma

Adding Daratumumab to Carfilzomib-Based Therapy in Resistant Myeloma: CANDOR Trial

Post-Hoc Analysis of Belantamab Mafodotin in Resistant Myeloma From DREAMM-2

Salvage Therapy Under Study for Resistant Myeloma With Extramedullary Disease

SOHO 2020: Cross-Study Comparison of Carfilzomib, Dexamethasone, and Daratumumab Dosing Regimens in Myeloma

Triplet Regimens Compared in Newly Diagnosed Multiple Myeloma: ENDURANCE Trial

Older Adults With Myeloma: Second Primary Malignancy and Lenalidomide Therapy

Do Diagnostic Pathways Determine Multiple Myeloma Severity?

SOHO 2020: Fixed-Volume Isatuximab in Resistant Multiple Myeloma

Chromosome 1q Abnormalities in Patients With Myeloma: Predictive of Inferior Outcomes?

Transplant-Ineligible Myeloma: Comparing Regimens With and Without Daratumumab

Multiple Myeloma and COVID-19: Treatment Lessons Learned